Tenax Therapeutics Nears Phase III Data Readout for Levosimendan in PH-HFpEF

Tenax Therapeutics is approaching a pivotal moment for its lead drug candidate, with the company nearing completion of enrollment in its first Phase III trial and expecting to report data in the second half of this year. The development program for its oral therapy, TNX-103 (levosimendan), is now entering its most consequential evaluation period for treating pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), a condition that currently lacks any approved therapies.

The company is nearing the end of enrollment in its first Phase III trial, a U.S.-Canada study targeting 230 randomized subjects. Tenax has already randomized more than the initial target of 230 patients, with final screening activities scheduled to conclude by the end of March. The first topline results from this Phase III trial are planned for release in the third quarter of 2026.

In parallel, management is progressing the global LEVEL-2 study, a second registrational trial designed to support the long-term clinical strategy. The company is beginning what it expects to be a roughly two-year recruitment period for this second Phase III trial, which was initiated in the fourth quarter of last year. Patient recruitment for LEVEL-2 is anticipated to continue through the end of 2027.

From a financial perspective, Tenax appears positioned to fund its operations through this crucial phase. The company's existing cash reserves are projected to be sufficient to sustain operations into 2027, with liquidity earmarked for advancing the ongoing Phase III programs and expanding the clinical pipeline. Furthermore, the company has strengthened its intellectual property portfolio by securing extended patent protection for subcutaneous formulations of levosimendan.

Management discussed the rationale for levosimendan in PH-HFpEF, framing it as primarily a vasodilator that lowers wedge pressure. According to the company's Phase II experience, patients experienced a 29-meter improvement in six-minute walk distance along with clear wedge pressure reductions, without a change in cardiac output. This pattern suggests the response is not driven by calcium sensitization in this population, but rather by vasodilation, with levosimendan acting as a potassium ATP channel activator in these patients.

The company views PH-HFpEF as a multi-billion dollar commercial opportunity, citing high prevalence and the absence of approved therapies. Tenax believes there are over 2 million patients in the United States with the condition and probably a roughly similar amount in Europe. The company's trials are recruiting across both the combined pre- and post-capillary PH (Cpc-PH) phenotype and isolated post-capillary PH (Ipc-PH), which supports the company's broader estimate of around 2 million U.S. patients.

In discussing the Phase II LEVEL study, management emphasized the use of invasive hemodynamic testing under exercise conditions, noting that no other PH-HFpEF program has tested invasive hemodynamic effects under exercise. The company cited significant reductions in wedge pressure, central venous pressure, and mean pulmonary arterial pressure in that setting, along with the observed six-minute walk benefit as a clinical improvement that had not been shown previously in this population.